Estrella Immunopharma raises ~$3.35M in PIPE at $1.50/share

Estrella Immunopharma, Inc.

Issued 2,233,334 shares at $1.50 each (premium to $1.00 close on May 29, 2025).
Net proceeds to fund Phase I STARLIGHT-1 trial of EB103 CD19-targeted T-cell therapy in NHL.
True-Up provision: additional shares if 12-month closing price below $1.50 (floor $0.20).
Company agreed to file resale registration statement for shares issued in PIPE.
Closing subject to customary conditions; investor support cited as confidence in ARTEMIS platform.

item 1.01item 3.02item 8.01item 9.01

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.